Clinical trial · Interventional
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer After D2 Gastrectomy (DRAGON-Adjuvant): a Multicenter, Open-label, Phase 3, Randomized, Non-inferiority Study
NCT07366528CI-TRIAL-00101630recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, open-label, phase 3, randomized, non-inferiority study aimed to investigate the effect on disease-free survival of adjuvant chemotherapy with oxaliplatin plus S-1 compared with adjuvant chemotherapy with docetaxel plus S-1 after D2 gastrectomy in patients with stage III gastric cancer.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adjuvant Chemotherapy | — | UNRESOLVED | — |
| Docetaxel | — | UNRESOLVED | — |
| Gastric Cancer (GC) | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Oxaliplatin | — | UNRESOLVED | — |
| Stage 3 Cancer | Gastric Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel plus S-1 | Drug | — | UNRESOLVED |
| Oxaliplatin plus S-1 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Oxaliplatin plus S-1
- description
- Patients will be treated with oxaliplatin plus S-1 as adjuvant therapy
- interventionNames
- Drug: Oxaliplatin plus S-1
- type
- ACTIVE_COMPARATOR
- label
- Docetaxel plus S-1
- description
- Patients will be treated with docetaxel plus S-1 as adjuvant therapy
- interventionNames
- Drug: Docetaxel plus S-1
Primary outcomes (1)
- measure
- 3-year disease-free survival rate
- timeFrame
- From randomization to 3 years after randomization
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. age 18 to 80 years old, male and female 2. histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction 3. patients underwent standard D2 gastrectomy and achieved R0 resection, and had no systemic therapy like neoadjuvant therapy 4. American Joint Committee on Cancer stage IIIA (T2N3a, T3N2, T4aN1, T4aN2, T4bN0), IIIB (T1N3b, T2N3b, T3N3a, T4aN3a, T4bN1, T4bN2), IIIC (T3N3b, T4aN3b, T4bN3a, T4bN3b), and has Lauren classification 5. with no evidence of metastatic disease 6. ECOG 0 to 1 7. Enough organ functions that can tolerate treatment: Absolute neutrophil count (ANC) ≥1.5x109/L, White blood count ≥3.5x109/L, Platelets ≥75x109/L, Hemoglobin (Hb) ≥80g/L, ALT/AST ≤2.5x ULN (for patient with liver metastasis ALT/AST ≤5x ULN), Serum bilirubin ≤1.5x ULN, Serum creatinine ≤1.5x ULN. 8. Woman of childbearing age should contracept for at least one month before screening and commit to using contraception throughout the entire study period and for the specified time after the study ends. 9. Signed informed consent and willing to follow the study protocol Exclusion Criteria: 1. other primary malignancies, except for cured skin tumors or cervical carcinoma in situ 2. severe complications that may lead to an expected survival time less than 5 years 3. uncontrollable comorbidities, such as infectious disease, chronic diseases like hypertension, diabetes, heart diseases. 4. allergic to study medication 5. bowel obstruction or other conditions affecting oral administration 6. organ functions that cannot tolerate study treatment 7. other conditions that patients are unsuitable for this study assessed by the investigators
References
Publications (0)
Data not yet available
No reference posted for this study.